Aroclor 1016 is a polychlorinated biphenyl (PCB) mixture produced by Monsanto. It is a complex mixture of 209 different PCB congeners, with varying chlorine atom substitutions on the biphenyl ring. Aroclor 1016 contains a higher proportion of highly chlorinated congeners compared to other Aroclor mixtures, resulting in a higher molecular weight. The specific composition of Aroclor 1016 varies depending on the manufacturing batch. Aroclor 1016 was widely used as a dielectric fluid in electrical equipment, a plasticizer in paints and plastics, and in hydraulic fluids. However, its use was discontinued in the 1970s due to its persistence in the environment and its toxicity. Aroclor 1016 is considered a persistent organic pollutant (POP) and is highly resistant to breakdown in the environment. It accumulates in the food chain, posing a risk to wildlife and humans. Aroclor 1016 has been linked to a variety of health effects, including cancer, reproductive problems, and developmental abnormalities. The study of Aroclor 1016 is important because it helps us understand the environmental fate and toxicology of PCBs. It also provides insights into the long-term health effects of exposure to these persistent pollutants. Research on Aroclor 1016 continues to be conducted to assess its impact on human health and the environment, as well as to develop methods for its remediation and removal from contaminated sites.'
ID Source | ID |
---|---|
PubMed CID | 38037 |
CHEMBL ID | 3183220 |
SCHEMBL ID | 4453361 |
MeSH ID | M0089073 |
Synonym |
---|
pcb 36 |
1,1'-biphenyl, 3,3',5-trichloro- |
aroclor 1016 |
12674-11-2 |
pcb-1016 |
hsdb 6352 |
arochlor 1016 |
chlorodiphenyl (41% cl) |
1,3-dichloro-5-(3-chlorophenyl)benzene |
NCGC00249197-01 |
ccris 8481 |
aroclor-1016 |
dsstox_cid_3883 |
cas-12674-11-2 |
NCGC00259797-01 |
tox21_202248 |
dsstox_rid_77218 |
dsstox_gsid_23883 |
38444-87-0 |
d998089l9e , |
3,3',5-trichlorobiphenyl |
unii-d998089l9e |
SCHEMBL4453361 |
3,3',5-trichloro-1,1'-biphenyl |
RIBGNAJQTOXRDK-UHFFFAOYSA-N |
CHEMBL3183220 |
J-005430 |
DTXSID50858937 , |
3,3',5-trichlor-biphenyl |
Q26841232 |
dtxcid503883 |
Excerpt | Relevance | Reference |
---|---|---|
" In much of the early development of behavioral toxicology, the pharmacological model has served as a valuable theoretical guide, especially with regard to dosing and kinetic parameters." | ( Use of the lesion model for examining toxicant effects on cognitive behavior. Bowman, RE; Levin, ED; Schantz, SL, ) | 0.13 |
" This is the first demonstration that environmental chemicals program AR function permanently at the dosage consumed by the general population." | ( Reproductive malformation of the male offspring following maternal exposure to estrogenic chemicals. Gupta, C, 2000) | 0.31 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 47.2519 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 20.9202 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
AR protein | Homo sapiens (human) | Potency | 5.8961 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 31.2322 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 52.5493 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 26.3370 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 19.9260 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 39.4064 | 0.0015 | 30.6073 | 15,848.9004 | AID1259401 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 58.9612 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 42.1133 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 48.1188 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1259385; AID1259395 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 41.4157 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 109.0900 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 59.4866 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 74.2278 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (26.92) | 18.7374 |
1990's | 8 (30.77) | 18.2507 |
2000's | 6 (23.08) | 29.6817 |
2010's | 5 (19.23) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.33) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (3.45%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 28 (96.55%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |